Xeris Biopharma Holdings, Inc. filed a current report on Form 8-K on September 9, 2026, disclosing that the company hosted a webinar providing an overview of its XP-8121 program and furnished an accompanying investor presentation and press release.

Key Highlights

  • Event date: The XP-8121 Program Overview webinar was held on September 9, 2026.
  • Disclosure type: The filing was made under Item 7.01, Regulation FD Disclosure.
  • Exhibits furnished: An investor slide presentation (Exhibit 99.1) and a press release (Exhibit 99.2) were furnished with the filing.
  • Program focus: The webinar covered the XP-8121 program, with senior management conducting discussions with investors using the slide presentation.
  • Filing status: The information in Item 7.01, including the two exhibits, is furnished and "shall not be deemed to be 'filed'" for purposes of Section 18 of the Securities Exchange Act of 1934, according to the filing.

Xeris Biopharma Discloses XP-8121 Investor Webinar Details

Xeris Biopharma Holdings, Inc., a Delaware-incorporated biopharmaceutical company listed on the Nasdaq Global Select Market under NASDAQ:XERS with common stock carrying a par value of $0.0001 per share, filed its current report disclosing an investor-facing webinar centered on the XP-8121 program. The company's principal executive offices are located at 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607. The filing was signed by Steven M. Pieper, the company's Chief Financial Officer.

According to the filing, senior management used a slide presentation during the webinar to discuss the XP-8121 program with investors. That presentation was furnished as Exhibit 99.1, while a press release announcing the webinar, dated September 9, 2026, was furnished as Exhibit 99.2. The filing notes that neither exhibit is deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

The company also stated that any reference to its investor relations website is provided as "an inactive textual reference only," and that the website's contents are not incorporated by reference into the current report. The registrant confirmed it is not an emerging growth company as defined under the applicable rules of the Securities Act of 1933 and the Securities Exchange Act of 1934.

What Was Disclosed

Xeris Biopharma Holdings, Inc. reported, under Regulation FD, that it held an XP-8121 Program Overview webinar on September 9, 2026, furnishing an investor presentation and a press release as exhibits to the filing. No financial results were included in this report.